BMY

Bristol-Myers Squibb Company Healthcare - Pharmaceuticals Investor Relations →

NO
25.1% ABOVE
↑ Moving away Was 22.5% last week
-15% -10% -5% 0% 5% 10% 15%+
Signal Threshold $50.72
14-Week RSI 48
Rel. Volume (14w) This week's trading vs. the 14-week average 0.9x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.01

Bristol-Myers Squibb Company (BMY) closed at $63.43 as of 2026-11-13, trading 25.1% above its 200-week moving average of $50.72. The stock moved further from the line this week, up from 22.5% last week. The 14-week RSI sits at 48, indicating neutral momentum.

Trading volume is running at 0.9x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.01 ratio) is neutral — neither side is clearly dominating.

Over the past 2793 weeks of data, BMY has crossed below its 200-week moving average 27 times. On average, these episodes lasted 27 weeks. Historically, investors who bought BMY at the start of these episodes saw an average one-year return of +4.1%.

With a market cap of $129.7 billion, BMY is a large-cap stock. The company generates a free cash flow yield of 4.9%. Return on equity stands at 44.0%, indicating strong profitability. The stock trades at 5.5x book value.

Over the past 33.9 years, a hypothetical investment of $100 in BMY would have grown to $1519, compared to $3136 for the S&P 500. BMY has returned 8.4% annualized vs 10.7% for the index, underperforming the broader market over this period.

Free cash flow has been growing at a 2.4% compound annual rate, with 4 consecutive years of positive cash generation.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: BMY vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After BMY Crosses Below the Line?

Across 21 historical episodes, buying BMY when it crossed below its 200-week moving average produced an average return of -1.5% after 12 months (median +3.0%), compared to +8.3% for the S&P 500 over the same periods. 52% of those episodes were profitable after one year. After 24 months, the average return was -10.0% vs +14.2% for the index.

Each line shows $100 invested at the moment BMY crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Bean Score Experimental

The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices BMY would reach each dislocation threshold.

Current Bean Score +0.61σ
Current FCF Yield 7.16%
Baseline Yield 7.43%
Historical σ 0.49pp

Dislocation Price Levels

Prices where BMY's Bean Score would hit each σ threshold. Valid until next earnings report (date TBD — last report: 2026-09-30).

LevelσPriceSignal
Deep Value+2σ$57.93Unusually cheap — analysis point
Value+1σ$61.78Cheap vs. own history
Fair Value+0σ$66.18Historical mean behavior
Expensive-1σ$71.25Expensive vs. own history
Deep Expensive-2σ$77.17Unusually expensive — analysis point

Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end

Recent Earnings

DateEPS Est.EPS ActualSurprise
2026-10-29$1.17$1.35+15.2%
2026-07-30$1.60$2.04+27.7%
2026-04-30$1.42$1.58+11.2%
2026-02-05$1.20$1.26+4.6%
Data depth: 2 quarterly baselines, 19 price observations — Limited history (4+ quarters preferred for reliability)

Signal Accuracy Collecting Data

The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"

21 / 13 weeks minimum

the write-ups I read Simply Wall St · Visual company reports and write-ups. Free tier covers five reports a month. referral

Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are analysis points: prices at which the yield deviation becomes unusual enough to justify the work. FCF values update quarterly with earnings; between reports, all movement is price-driven.

Dislocation Scores Experimental

Each score measures deviation from BMY's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

⚠ Earnings quality deteriorating — net income is outrunning free cash flow vs this company's own norm. Cheapness signals here deserve extra scrutiny.
Yield Dislocation -0.27σ Dividend yield vs own 10-yr norm
Drawdown Score -0.10σ Distance from line vs own history
Sector-Relative +0.48σ Vs sector median this week
Buyback Acceleration +0.9pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity N/A TTM buys / market cap, percentile of buyers
FCF Yield vs History -8.2pp Vs own recent annual mean
Earnings Quality Deteriorating Accrual gap trend (+16.8pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. Each one is an analysis point, a reason to open the filings. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Historical Touches

BMY has crossed below its 200-week MA 27 times with an average 1-year return of +4.1% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
May 1973Jul 1973911.8%-16.5%+23349.7%
Aug 1973Jan 19757742.8%-22.2%+22343.7%
Feb 1978Mar 197833.4%+16.7%+20435.2%
Oct 1978Oct 197812.8%+9.2%+19384.7%
Jul 1979Jul 197910.7%+32.9%+18209.3%
Mar 1980Mar 198032.3%+83.2%+18136.9%
Jan 1993Jan 199510517.9%+2.3%+1406.1%
Jul 2000Aug 200051.4%+14.0%+259.4%
Sep 2000Sep 200010.2%+16.4%+248.3%
Apr 2001Jul 2001138.5%-43.3%+218.1%
Sep 2001Sep 200117.4%-51.0%+229.7%
Oct 2001Nov 200124.0%-50.8%+215.5%
Nov 2001Feb 200622060.4%-48.9%+211.3%
Aug 2006Aug 2006310.7%+48.3%+572.7%
Jan 2008Dec 20084722.5%+3.3%+456.9%
Jan 2009Jul 20092917.9%+17.4%+440.3%
Oct 2016Nov 201646.6%+34.7%+81.9%
Jan 2017Feb 2017512.6%+29.9%+82.7%
Mar 2017Jul 2017184.1%+19.5%+65.4%
Apr 2018Jul 20181511.4%-8.3%+70.0%
Oct 2018Oct 20195421.1%-7.2%+49.2%
Mar 2020Mar 202029.7%+33.7%+70.2%
Jul 2023Aug 202331.9%-13.8%+20.2%
Sep 2023Nov 20246332.0%-16.0%+21.3%
Dec 2024Jan 202562.9%-1.4%+24.7%
Feb 2025Feb 202535.4%+14.5%+21.0%
Mar 2025Dec 20253719.5%+13.2%+23.1%
Average27—+4.1%—

Frequently Asked Questions

Is BMY below its 200-week moving average?

No. Bristol-Myers Squibb Company (BMY) is currently 25.1% above its 200-week moving average of $50.72. It would need to fall to $50.72 to cross below the line.

What is BMY's 200-week moving average price?

Bristol-Myers Squibb Company's 200-week moving average is $50.72 as of 2026-11-13. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when BMY drops below its 200-week moving average?

BMY has crossed below its 200-week moving average 27 times in our data. On average, buying at that moment produced a one-year return of +4.1%. These dips have historically been decent entry points. These episodes lasted 27 weeks on average.

Is BMY a good value right now?

Here's what our data says about BMY as of 2026-11-13: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 48. Free cash flow yield is 4.9%. Return on equity is 44.0%. Price-to-book is 5.5x. This is not a buy or sell recommendation — always do your own research.

How does BMY compare to the S&P 500?

Over the past 33.9 years, $100 invested in BMY would have grown to $1519, compared to $3136 for the S&P 500. That's 8.4% annualized vs 10.7% for the index. BMY has underperformed the broader market over this period.

Does BMY pay a dividend?

Yes. Bristol-Myers Squibb Company currently pays a dividend yield of 397.00%.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-11-13